Overall, the Magee Equation 3 serves as a practical, affordable, and effective tool for predicting tumor response and recurrence risk in ER/PR-positive, HER2-negative breast cancers, making it valuable for routine oncologic practice. This evidence concerns the gene ESR1 and neoplasm.